Feasibility Study of SOL (S-1,Oral Leucovorin,and Oxaliplatin) for Colorectal Cancer in China (SCI-101)

Shen Lin

Status and phase

Completed

Phase 2

Phase 1

Conditions

Colorectal Cancer

Treatments

Drug: S-1, leucovorin, oxaliplatin

Study type

Interventional

Funder types

Other

Identifiers

NCT01110941

SOL feasibility study

Details and patient eligibility

About

S-1 is an oral fluoropyrimidine with demonstrated efficacy on gastric cancer and colorectal cancer. The new regimen with Oxaliplatin and leucovorin is expected to achieve more encouraging efficacy on colorectal cancer. This study is to explore the feasibility of the SOL regimen on efficacy and tolerability on Chinese colorectal cancer patients.

Full description

Endpoints:
Primary endpoints: adverse drug reaction
Secondary endpoints:
- Overall Response Rate：ORR
- Progress Free Survival: PFS
- Time to Treatment Failure：TTF

Enrollment

20 patients

Sex

All

Ages

20 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Advanced unresectable or recurrent colorectal cancer patients which meet the following criteria:
- Willing to sign ICF
- Could orally take investigational product
- Pathology diagnosis is adenocarcinoma
- Above 20 years
- No previous treatment(including: radiotherapy,chemotherapy and immunotherapy)
- For recurrent cases, if the patient had received adjuvant chemotherapy that didn't include S-1 and L-OHP in 180 days ago, he/she could be enrolled in
- With target lesions with diameter which is longer than 1cm in spiral CT or MRI examination within 30 days
Lab test within 15 days meet following criteria
- Hemoglobin higher than 9.0g/dL
- Leukocyte higher than 12,000/mm3
- Neutrophil higher than 2,000/mm3
- PLT higher than 10.0 104/mm3
- Bilirubin lower than 1.5 times of upper limit of normal range
- AST,ALT,ALP lower than 2.5 times of upper limit of normal range
- Creatinine lower than upper limit of normal range

When patient has liver metastasis or bone metastasis, the value of AST,ALT,ALP could be within 5 times of upper limit of normal range

ECOG 0 or 1
Expected survival time more than 90 days

Exclusion criteria

The patient who meet the following criteria should be excluded from this trial
Patients who have severe drug allergic history(including: platinum related drugs,5-FU,FT,LV,5-HT3 receptor antagonist)
Attended other clinical trial within 4 weeks
Received transfusion of blood,related products or G-CSF within 15 days
Received surgery within 4 weeks and the effect hadn't vanished
Have diarrhea
Have complication of active infection(infection caused fever higher than 38℃)
Have complication of poor controlled hypercalcemia,hypertension,diabetes
Have complication of severe ECG abnormal or other heart disease which will affect clinical treatment(including: cardiac dysfunction,myocardial infarction,angina)
Have complication of severe pulmonary disease(including:interstitial pneumonia,pulmonary fibrosis,severe emphysema)
Have complication of psychiatric disorder which will affect clinical treatment or have history of CNS disease
Have complication of active gastrointestinal bleeding
Have pleural effusion,ascites or pericardial effusion that need drainage
Have complication of multiple bone metastasis
Have severe complication(including:ileus,renal insufficiency,hepatic insufficiency,cerebrovascular disturbance)
Have brain metastasis or suspicious brain metastasis
Have active multiple primary cancer
Female patients who are in pregnancy or lactation and patients who are not willing to take contraception measures
Investigator judge not eligible to this trial